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Experts opinion: implantable continuous 
glucose monitoring system — innovation  
in the management of diabetes
ABSTRACT
Continuous glucose monitoring (CGM) systems have 
revolutionized the treatment and monitoring of dia-
betes. These devices are recommended for diabetic 
patients treated with insulin, especially with recurring 
episodes of hypoglycemia or large circadian variation 
of glucose levels. CGM allows more effective adjust-
ment of insulin doses to blood glucose trends, resulting 
in better metabolic control: more time spend in glucose 
target range, lower time spend in hypoglycemic range, 
lower glucose variability and improved quality of life 
of patients and their family members. Real time CGM 
provides patients not only with continuous informa-
tion on glucose levels but also alerts for hypo- or 
hyperglycemic events. 
Traditional transcutaneous CGM have some limitations, 
which can be resolved by the system with an implant-
able sensor. The Eversense CGM is the only long-term 
implantable rtCGM. The subcutaneous implantation 
procedure has proved to be simple and uncomplicated. 
This CGM system can be recommended in particular 
for patients who, due to their profession and sports 
discipline, cannot or do not want to use traditional 
transcutaneous sensors. Further groups are patients 
with skin complications associated with the use of 
traditional sensors, people who perceive frequent 
sensor replacement as a burden or would benefit from 
on-body vibration alerts. The studies showed that the 
patients were satisfied with Eversense, and the major-
ity used it several times after the study ended. The main 
reason for resigning from the next implantation was 
cost of the device. (Clin Diabetol 2019; 8, 6: 318–328)
Key words: long-term implantable glucose 
monitoring, real-time continuous glucose 
monitoring system, clinical practice opinion
Introduction
The burden of diabetes is steadily increasing. 
Current estimations implicate that there are more 
than 450 million people with diabetes worldwide and 
almost half of them are undiagnosed. According to 
the International Diabetes Federation, it is expected 
that the prevalence of diabetes will rise to 693 million 
people by 2045 [1].
It is commonly known that chronic hyperglycemia 
can affect the structure and impair the function of many 
tissues in the body, especially the vascular system. Dia-
betic complications and comorbid conditions primar-
ily determine the quality of life, and they are mainly 
responsible for the increased mortality of patients [2].
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So far, the main marker which is used to evaluate 
the risk of long-term diabetes complications is glycated 
hemoglobin (HbA1c). HbA1c level is an important indica-
tor of glycemic control. Regular HbA1c level measure-
ments are also helpful in the evaluation of diabetes 
treatment efficiency [3]. 
Nowadays, the overall goal of diabetes control 
in diabetic patients is HbA1c level ≤ 7.0% [4]. Better 
long-term diabetes control resulting in a reduction 
in HbA1c is associated with decreased risk of chronic 
complications and mortality [5]. However, it should be 
emphasized that HbA1c level does not reflect glycemic 
variability, which emerged recently as another possi-
ble risk factor for vascular dysfunction in diabetes [6]. 
The limited control of glycemia drives also the higher 
risk of hypoglycemia. Fear of hypoglycemia results in 
maintaining elevated blood glucose levels and it is the 
important cause of insufficient metabolic control of 
the disease and reduces the possibility of treatment 
intensification [7]. Currently, hypoglycemia is consid-
ered to be the greatest obstacle to achieve metabolic 
control of diabetes. Moreover, severe hypoglycemia 
has been also considered to be one of the predictors 
of macrovascular events and also increased mortality 
in patients with diabetes. 
The evaluation of glucose variability and the risk of 
hypoglycemia has a great impact on the management 
of diabetes. It allows assessment of the effectiveness 
of therapy and provides guidance in selecting the ap-
propriate insulin dosage schedule. 
Therefore, blood glucose monitoring and appropri-
ate management of glycemia is important not only to 
prevent chronic complications by reducing hypergly-
cemia but also to avoid hypoglycemic episodes and to 
decrease glycemic variability [8, 9].
Blood glucose monitoring as a part  
of the integral care of diabetic patients 
Current monitoring and retrospective evaluation of 
blood glucose levels are essential parts of adequate dia-
betes treatment [4]. BG monitoring allows patients to 
assess their response to the treatment, decrease the risk 
of hypoglycemia, and to determine whether they are 
achieving glycemic control. Detailed information about 
blood glucose levels can be helpful in the adjustments 
in therapy and lifestyle activities and simultaneously to 
prevent diabetes-related complications. This is typically 
achieved using conventional personal blood glucose 
meters to measure finger-prick capillary blood samples 
[10]. The recommended frequency of self-monitoring 
of blood glucose (SMBG) is mainly dependent on the 
type of diabetes, treatment regimen and susceptibi-
lity to hypoglycemia. Intensification of the treatment 
is associated with the need for more frequent blood 
glucose monitoring [4]. 
Regardless of the treatment used, all patients 
should check blood glucose levels in case of feeling 
unwell, a sudden illness or suspected hypoglycemia. 
They should monitor blood glucose before planned 
physical activity and before activities associated with 
particular dangers of hypoglycemia (e.g. driving). 
However, testing six to eight or more times daily 
SMBG may burden patients and may result in non-
compliance. Therefore, it is also recommended to 
ensure that patients are properly instructed and are 
given regular evaluation and follow-up. Proper SMBG 
requires patient education regarding glucose meter 
use, interpretation of readings, and further manage-
ment steps [4]. 
Self-monitoring of blood glucose was the standard 
of care for patients with diabetes for a few decades. 
So far, it is a widely used method of current glucose 
monitoring in Poland. However, SMBG has notable limi-
tations. It is insufficient to diagnose all acute episodes 
of hyper- and hypoglycemia and thereby to get a full, 
daily profile of glycemia, which can allow for rapid 
patient reaction or adjustment of diabetes treatment. 
A glucose meter measures glucose levels at a single 
moment in time, and therefore, it does not indicate 
the direction or rate of change of glucose levels. Using 
glucose meter data alone may result in inappropriate 
therapy decisions (such as administering correction 
insulin when blood glucose levels are falling). Accord-
ingly, SMBG often fails to detect nocturnal and asymp-
tomatic hypoglycemia [10, 11]. Moreover, obtaining 
glucose data via glucose meter is dependent upon the 
patient’s decision to self-monitor. It requires a finger 
prick to obtain a blood sample, and it results in pain 
for the patient, which also affects patient compliance 
with glucose measurements.
Continuous glucose monitoring 
The introduction of continuous glucose moni-
toring (CGM) systems in 1999 have slowly changed 
standards of medical care in diabetes. In recent years, 
blood glucose monitoring has been revolutionized by 
the development of different systems for continuous 
glucose monitoring (CGM). 
Currently, there are two types of new technological 
devices available to measure glucose levels in the inter-
stitial fluid through sensors inserted subcutaneously: 
real-time CGM and Flash Glucose Monitoring (FGM, 
intermittent scanning continuous glucose monitoring 
— is-CGM). Both systems provide information about 
current and previous glucose levels, as well as glucose 
trends and anticipated future glycemic status, but each 
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technology has its unique features. FGM provides glu-
cose information on demand. CGM measures glucose 
automatically and, as often as every five minutes, which 
generates 288 measurements per day. RtCGM provides 
for patients not only continuous current information 
on glucose levels in interstitial fluid over the whole day, 
but also alerts for hypo- or hyperglycemic events and 
rapid glucose trends [11]. 
Comparison of CGM systems
In Poland, there are a few real-time CGM systems 
available, e.g., Guardian™ Connect (Medtronic), Dex-
com G4, Dexcom G5 and the Eversense CGM. Patients 
who choose to use CGM have several options available 
to them, standalone devices or insulin pumps integrat-
ed with CGM (MiniMed® Real Time™ 722, MiniMed® 
Veo™, MiniMed® 640G™ Medtronic) [12]. 
The Medtronic and Dexcom systems utilize transcu-
taneous sensors (transcutaneous real-time CGM — TC 
rtCGM). They consist of three components: a disposable 
sensor that is inserted into the subcutaneous tissue to 
measure glucose levels, a transmitter that attaches to 
the sensor, and a receiver (stand-alone device, insulin 
pump, smartphone, smartwatch) that displays and 
stores glucose information [12].
The Eversense CGM is the only, long-term implant-
able real-time CGM (LTI rtCGM). The system consists of 
an implantable, fluorescence-based, cylindrical glucose 
sensor, a removable external smart transmitter and 
a mobile medical application that displays glucose in-
formation and operates on a mobile device that allows 
users to review current and historical glucose data in 
real-time. The Eversense system is indicated for up to 
180-days wear time in adults only [12]. 
FreeStyle Libre, the first flash glucose monitoring 
(FGM) system, was approved in Autumn 2014. FGM 
also measures glucose concentration in the interstitial 
fluid. However, it differs from other CGM technology 
in several ways. FGM is factory calibrated and does 
not require capillary blood glucose calibration. Sen-
sor glucose levels are not continually displayed on 
a monitoring device but instead are displayed when the 
sensor is “flashed” with a reader device on demand. 
The FGM reader also displays a plot profile of the last 
8 hours, derived from interpolating glucose concentra-
tions recorded every 15 minutes. Therefore, when the 
patient with diabetes performs ≥ 3 sensor scans per day 
at ≤ 8-hour intervals, the FGM records 24-hour glucose 
profiles. The sensor can be worn continuously for up 
to 14 days, but it does not provide low or high glucose 
alarms in first-generation system. FGM system provides 
protection against hypoglycemia during the day, but it 
cannot detect nocturnal hypoglycemia when the user is 
sleeping or warn the physically active individual about 
pending hypoglycemia [13–15]. 
Also, all CGM systems can simultaneously transmit 
data to the cloud to share information in real-time. To 
date, insulin pumps integrated with CGM do not have 
such a function.
Jafri et al. compared available CGM by testing the 
performance of the Dexcom G5, Abbot Freestyle Libre 
Pro, and Senseonics Eversense during a 6-week, free 
life, outpatient bionic pancreas study involving 23 
subjects with type 1 diabetes who wore all 3 devices 
concomitantly. The primary outcome was the mean 
absolute relative difference (MARD) vs. plasma glucose 
level measured with a glucometer. All 3 CGM systems 
produced higher average MARDs than during in-clinic 
studies. In the 3-way comparison Eversense achieved 
the lowest nominal MARD (14.8%) followed by Dex-
com G5 (16.3%) and Libre Pro (18.0%). The pointing 
accuracy of the Eversense was significantly better than 
two other CGM systems [16].
Clinical use of continuous glucose monitoring
CGM and FGM systems are becoming increas-
ingly prevalent in clinical practice because using it can 
reduce patients’ discomfort and provide vastly more 
detailed glucose variability data. These systems can 
supply insight into the duration, frequency of hypo- 
and hyperglycemia and fluctuations in blood glucose 
levels. Therefore, they can be helpful to improve overall 
glycemic control by identifying episodes and preventing 
periods of hypoglycemia and hyperglycemia [15, 17].
Continuous glucose monitoring allows more ef-
fective adjustment of insulin doses to blood glucose 
trends, resulting in better metabolic control: more time 
spent in the glucose target range, a reduced number of 
hypoglycemia episodes (or lower time spend in hypo-
glycemic range), lower glucose variability and improved 
quality of life of patients and their caregivers [16]. 
According to the Diabetes Poland guidelines, the 
use of continuous glucose monitoring systems, includ-
ing rtCGM and FGM is particularly indicated in patients 
with labile diabetes type 1, in patients with frequent 
hypoglycemic episodes. RtCGM is particularly indicated 
in patients with hypoglycemia unawareness, frequent 
nocturnal hypoglycemia and children < 10 years of 
age. In these patient groups, it is also recommended to 
use insulin pumps integrated with CGM, with a func-
tion of automatic temporary insulin suspension of the 
insulin infusion at low blood glucose values or at risk 
of hypoglycemia [4].
Initially, as recommended, patients using CGM 
prior to making therapeutic decisions should confirm 
the reading with a conventional meter. Currently, pa-
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tients can make therapeutic decisions based on the Dex-
com G5, the Dexcom G6, FGM. In June 2019, the FDA 
approved a nonadjunctive indication for the 90 days 
system Eversense CGM. The FDA reviewed device per-
formance data and proposed changes to the Eversense 
App (that support non-adjunctive use) and determined 
that Eversense is safe for making treatment decisions 
(such as dosing insulin and consuming carbohydrates) 
based on CGM glucose readings and trend arrows. 
Szypowska et al. conducted a meta-analysis of 
seven RCTs to explore the potential beneficial effects 
of the use of real-time CGM in patients with type 1 
diabetes mellitus. This analysis showed that the use 
of real-time CGM for over 60–70% of time provides 
a superior benefit over self-monitoring of blood glucose 
concerning HbA1c reduction. The improvement in HbA1c 
in patients using real-time CGM was achieved without 
an increase in severe hypoglycemia. The reduction 
in HbA1c was noted not only in patients with poorly 
controlled type 1 diabetes but also in well-controlled 
subjects. The superiority of real-time CGM over SMBG in 
lowering HbA1c was also confirmed in pump users [18].
In general, the choice of an optimal glucose moni-
toring device should be dependent on the patient’s 
clinical indications or lifestyle restrictions [13, 19]. 
Patients treated with intensive insulin therapy have a 
wide choice of glucose monitoring devices according 
to their personal preferences. The proposition of the 
decision algorithm for the use of specific devices for 
glucose monitoring was presented in Table 1 [20]. 
Education process of patients and physicians 
about optimal using of CGM
CGM systems provide real-time data on interstitial 
glucose level, direction and rate of change in blood 
glucose levels. However, users of CGM may not be able 
to make optimal usage of this additional information 
without proper education. The appropriate interpreta-
tion of measured parameters to make correct therapeu-
tic decisions is very important. Therefore, using CGM 
has to be supported with education of patients. Use 
of CGM/FGM requires structured education regarding 
appropriate expectations towards this system and 
proper interpretation of current readings including 
glucose trends [4]. 
The training for rtCGM should also include the 
principles of system functioning, its calibration and 
placing a sensor. Multiple alarms can be set to alert us-
ers if blood glucose increases or drops beyond defined 
target ranges. The most successful education programs 
emphasize training on self-management, including spe-
cific rules to adjust the insulin dose based on glucose 
data. Patients who understand how to interpret trend 
arrows have the best outcomes. At the time, when 
the trend arrow indicates a falling glucose level, then 
carbohydrates should be consumed, or dose of the 
prandial insulin should be decreased, and when the 
trend arrow indicate a rising glucose level, then the 
dose of insulin should be increased or physical activity 
should be started. Optimal using of CGM allows the 
patients to make lifestyle adjustments and therapeutic 
changes to improve their glycemic control [11].
The optimal training includes three parts: the prin-
ciples of sensor technology, the operational aspects of 
the device, and the interpretation of the provided data. 
This training should commence 1 week before starting 
using the system. 
Also, some physicians lack the appropriate level of 
knowledge to use CGM as part of their practices. There 
is need for considerable education regarding inter-
Table 1. Decision algorithm for glucose monitoring according to Clinical Practice Recommendations on the Routine Use 
of Eversense [15]
SMBG isCGM/FGM TC rtCGM LTI rtCGM
Intensified insulin therapy + + + +
High glycemic variability 
Committed to improved self-management + + +




Fear of pain or needle phobia 
Physically handicapped (visual, hearing, dexterity impairment)
History of skin problems +
Need for vibration alerts 
Need for transient removal of external devices
isCGM — intermittent scanning continuous glucose monitoring; LTI rtCGM — long-term implantable real-time CGM; SMBG — self-monitoring of blood  
glucose; TC rtCGM — transcutaneous real-time CGM
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pretation of CGM results for the physicians and other 
healthcare workers. Educational programs focused on 
these knowledge and coverage gaps will enable profes-
sionals to provide improved care of diabetic patients 
[11]. According to the Recommendations from the 
International Consensus on Time in Range, both medi-
cal staff and patients should know clinical targets for 
CGM data interpretation [21].
Senseonics Eversense CGM System
Description of the system and insertion  
procedure
Eversense is a novel implantable subcutaneous 
CGM system produced by Senseonics Inc. It was de-
signed to address several of the currently available 
CGM systems limitations. Eversense CGM sensor is the 
first one approved for long-term use and it can monitor 
blood glucose levels every five minutes for up to 90–180 
days, and thus it allows to reduce the inconvenience 
and discomfort of frequent sensor insertion procedures. 
Eversense CGM system differs from other systems 
currently on the market in that the sensor is implanted 
subcutaneously by a doctor; the removable smart 
transmitter is placed on the skin over the sensor and 
can be taken on and off as desired by the patient [22].
CGM systems based on electrochemical- and 
enzymatic- methods are often a subject of inter-
ference with substances such as ascorbic acid, 
paracetamol, dopamine or maltose. Eversense is 
a fluorescence-based, therefore, these substances do 
not affect the sensor readings. It has also a silicone 
ring that contains an anti-inflammatory steroid drug 
(dexamethasone acetate). The system provides con-
tinuous glucose measurements over a 40–400 mg/dL 
range. The sensor requires twice-daily calibration. The 
Eversense smart transmitter is worn over the sensor and 
wirelessly powers it to initiate the glucose measure-
ment and the transfer of data to the Mobile Medical 
Application (MMA). The transmitter can be removed 
at any time without the need for sensor replacement, 
allowing greater convenience and lifestyle flexibility. In 
addition, hypoglycemic and hyperglycemic alerts and 
notifications are provided on a mobile device. Addition-
ally, the patient experiences on-body vibratory alerts 
from the transmitter even when the mobile device is not 
nearby. Thus, Eversense CGM system gives the desired 
flexibility and freedom to test blood glucose anywhere 
at any time and share and analyze their personalized 
data securely via a smart app. It is also water-resistant 
submerged in 1 meter for up to 30 minutes and it func-
tions perfectly while the users take a shower or swim. 
The Eversense Mobile App runs on a compatible mobile 
device to receive and display the sensor glucose data 
from the Eversense Smart Transmitter. It eliminates the 
need to carry a separate receiver device. However, it is 
also important to check phone compatibility for CGM 
mobile applications before insertion. It is also able to 
set up a temporary glucose profile with custom high 
and low target and alert levels [22]. 
The Eversense CGM System Kit comes in three pack-
ages: the sensor pack, the insertion tools pack, and the 
smart transmitter pack. The sensor is shipped sterile 
inside a protective holder for safe handling purposes. 
The Eversense insertion tools pack contains the incision 
template, blunt dissector, insertion tool and adhesive 
patches. The incision template is used to guide and 
mark the incision area on the skin surface by aligning 
the marking template to the marked outer edges of the 
smart transmitter when placed in a comfortable posi-
tion. The suggested insertion location is approximately 
at the midway point between the acromion process 
and the lateral epicondyle. The insertion should avoid 
areas with loose skin (such as back of arm), scar tis-
sue, tattoo or nevus. During the procedure, the patient 
should be positioned in a reclined position, preferably 
on their side, with their elbow flexed up to 90 degrees 
and their palm resting on their chest or abdomen. The 
insertion area should be cleaned and disinfected before 
the application. Local anesthetic should be injected 
approximately 5 mm along the planned incision and 
approximately 30 mm perpendicular to the planned 
incision which is the planned canal of the blunt dis-
sector tool [22].
The attached blunt dissector (Fig. 1A) is used to 
create the subcutaneous pocket for insertion of the 
sensor. This tool has two depth guards to help prevent 
the pocket from being made too deep in the skin. The 
depth guards have guide marks to assist in determining 
the length of the subcutaneous pocket for placing the 
sensor. The insertion should be made approximately 
5 mm at the insertion location in such way that it will 
be able to create an appropriately sized subcutaneous 
pocket approximately 3–5 mm below the skin surface. 
The blunt dissector should be moved toward the shoul-
der while maintaining the metallic and plastic parts 
of the tool in close contact with the skin to ensure 
the smallest possible angle of the pocket with respect 
to the skin. The pocket should not be created more 
than 3–5 mm below the skin. If the sensor is placed 
too deep, it may be difficult to communicate with the 
smart transmitter or to be removed, therefore recent 
changes made to the blunt dissector should prevent 
placement mistakes [22].
To insert the sensor inside the subcutaneous pock-
et, the insertion tool has to be used. It has two guide 
marks on the cannula to assist in proper placement. 
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The tip of the insertion tool should be placed into the 
incision opening. Firstly, the insertion tool has to be 
unlocked by a pushing down on the back of the thumb 
slide (Fig. 1B). The sensor is deployed into the pocket by 
a retracting of the thumb slide (Fig. 1C). Before remov-
ing the insertion tool from the incision, the insertion area 
should be lightly palpated to confirm that the sensor is 
in place. The incision should be closed and dressed in 
the appropriate manner using adhesive skin closure or 
suture and dressing, making sure the two sides of the 
incision are closed together. Adhesive patches, included 
with the Eversense insertion tools pack, have an adhesive 
side that attaches to the back of the smart transmitter 
and a silicone adhesive side that attaches to the skin. It 
is important to inform the patient that adhesive patches 
should be replaced daily [22].
Even though, at first sight, the required minimally 
invasive procedure exceeds the area of experience for 
many diabetologists, the technique is easy to learn 
when performed with proper training, oversight, and 
attention to detail. Therefore, any physician interested 
in undertaking the procedure should be accompanied 
and consequently certified by the company’s clinical 
training manager during the first several insertions 
and removals to ensure the required training to comply 
with the highest quality standards [20]. Recently in 
Poland, there are 32 doctors who have sufficient expe-
r ience (3 training insertions of a sensor) to carry out of 
implementation procedure. Furthermore, 27 doctors 
carried out 3 or more insertions and removal of the 
Eversense system and thus obtained a full certificate. 
Above procedure can be carried out in one of 30 clinics 
or facilities, especially in large cities. 
Clinical experience
Long-term accuracy and clinical utility of Eversense 
system have been validated in prospective clinical trials 
(Table 2). In the multinational, multicenter European 
PRECISE trial, the safety and accuracy of the Eversense 
CGM system was investigated. It also assessed sensor 
lifetime, system wearout time, participant reported out-
come measures, and parameters of glycemic control. 
The Eversense system was studied in 71 participants 
aged 18 years and older with type 1 and type 2 diabetes 
during 180 days. CGM accuracy was assessed during 
eight in-clinic visits with the mean absolute relative 
difference (MARD) for venous reference glucose values 
> 4.2 mmol/L. The MARD value was 11.1% and 81% of 
hypoglycemic events were detected by the CGM system 
within 30 min. HbA1c improved in the study group from 
7.54% (59 mmol/mol) at baseline to 7.19% (55 mmol/ 
/mol) at the end of study. No device-related serious 
adverse events occurred during the study. The results 
from this study indicated that the use of a long-term 
Eversense CGM sensor is both effective and safe and 
provides specific usability benefits [23].
Barnard et al. determined acceptability and impact 
of an Eversense CGM sensor (as part of the PRECISE 
trial). Fifty-one participants took part in the study. 
Quantitative psychosocial assessments were admini-
stered at 90 days to participants to explore patient-
-reported outcomes associated with an implanted sensor. 
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Key issues included impact of device on perceptions of 
diabetes self-management and diabetes control, usability, 
safety, social relationships, and fear of hypoglycemia. The 
system was rated highly on ease of use, convenience, and 
comfort. CGM Impact Scale results showed that 86% of 
participants reported feeling better about their diabetes 
control. Furthermore, 73% felt safer while sleeping and 
78% more confident about avoiding serious hypoglyce-
mia. It was concluded that the Eversense CGM sensor 
was acceptable to participants and use of the system 
was associated with minimized burden of diabetes [24].
In 2018, there were also results of PRECISE II trial 
published. It was a nonrandomized, blinded, prospec-
tive, single-arm, multicenter study that evaluated the 
accuracy and safety of the Eversense CGM system among 
adult participants with T1D and T2D. Ninety participants 
were enrolled and each received the CGM system. The 
primary endpoint was the MARD between paired Ever-
sense and reference measurements through 90 days 
post insertion. The overall MARD value against refer-
ence glucose values was 8.8%, which was significantly 
lower than the prespecified 20% performance goal for 
accuracy. The system had a favorable safety profile for 
its intended use. Clinicians with limited to no surgical 
experience were able to insert and remove the sensor 
without difficulty after appropriate training. The results 
of PRECISE II trial demonstrated that the use of Eversense 
sensor for a long-term is accurate and safe [25].
Aronson et al. conducted a prospective, single-
centre, single-arm, 180-day study to evaluate the ef-
fectiveness and safety of the implantable CGM system 
in adolescent and adult subjects with T1D. Accuracy 
measures included mean absolute relative difference 
(MARD), 15/15% agreement between CGM glucose and 
blood glucose measured by SMBG and surveillance er-
ror grid analysis. Overall MARD was 9.4%. CGM system 
agreement at 15/15% through 60, 120 and 180 days was 
82.9%, 83.6% and 83.4%, respectively. Surveillance error 
grid analysis showed 98.4% of paired values in clinically 
acceptable error zones. No insertion/removal or device-
-related serious adverse events were reported. Results 
of above study confirmed that the Eversense XL CGM 
system is safe and accurate through 180 days in a pri-
marily adolescent population of subjects with T1D [26].
Clinical experience in Poland
We have also collected information on experience 
with Eversense CGM in various clinical centers in Poland.
First implantation of the Everense sensor was made 
on 22 October 2017 in Raszeja Hospital in Poznan 
(Department of Internal Medicine and Diabetology 
Poznań University of Medical Sciences). The implan-
tation/reimplantation procedure is performed in an 
outpatient clinic. An earlier qualifying visit is indicated 
during which the patient’s expectations and possible 
contraindications to the procedure are discussed. The 
procedure along with the preparation of the patient 
takes about 20–30 minutes. The implanting time usually 
does not exceed 15 minutes. The removal of the sensor 
is less predictable in time. It can last very short, but it 
can also be extended up to 30 minutes, especially when 
it is necessary to locate the sensor using an ultrasound 
scanner. Performing over 80 procedures of implanta-
tion and reimplantation, no complications were found. 
In no case did the wound require sewing. There was 
no infection, hematoma, non-healing wound, sensory 
disturbances, skin changes, allergic reaction. During 
one removal operation, ultrasound was used to find 
the sensor. Some patients were examined by physi-
cian 2 days after surgery to evaluate and change the 
dressing. In one case it was required to replace the 
steri-strips. Most of the patients stayed in contact with 
their doctors via telephone. Steri-strip were removed 
by patients themselves on the 6–7th day after the pro-
cedure. Regardless of whether the patients used insulin 
pen or a personal insulin pump, everyone was satisfied 
with Eversense. The majority, despite emphasizing the 
discomfort of the implantation procedure, had it car-
ried out several times. Patients who resigned from the 
next implantation usually did so for financial reasons.
In the Central Clinical Hospital of the Medical 
University of Lodz the Eversense sensor implementa-
tion procedure was introduced in January 2018. So 
far, over 80 procedures of implantation, removal and 
Table 2. Parameters characterizing the accuracy and safety of the Eversense CGM (based on results of clinical trials)
Study HbA1c reduction














PRECISE 1 0.4% 11.6% 23.5 59.9% 81%
PRECISE 2 0.5% 8.5% 23.4 57.6% 93%
PRECISION 0.3% 9.6% 23.4 59.0% 95%
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reimplantation of sensors have been performed. This 
CGM system was offered mainly to patients who, due to 
their profession and sports discipline, could not or did 
not want to use traditional transcutaneous sensors. Fur-
ther groups were patients with skin reactions associa - 
ted with the use of traditional sensors or patients who 
perceive frequent sensor replacement as a burden or 
benefited from on-body vibration alerts. 17 patients are 
now using the third sensor. The main reason for not 
continuing this CGM system is the price of the device. 
In the opinion of doctors from this centre, the sensor 
implementation was very simple and not a time con-
suming procedure. Removal of the sensor was usually 
an easy and short procedure. Problems while removing 
the sensor occurred only in two patients. Both patients 
required more lignocaine for anaesthesia and both 
needed ultrasonography to locate the sensor.
The next clinical experiences came from Clinical 
Diabetology Center in Krakow. The center has been 
implanting the sensors since August 2018 in patients 
with diabetes coming to the Clinic or directed by 
doctors from the Malopolska province. So far, 25 suc-
cessful implantations and 13 sensor exchanges have 
been carried out. There were no complications both 
for implantation and replacement. The subcutaneous 
session implantation procedure with the provided 
tools proved to be simple and uncomplicated. Also, 
there were no difficulties in attaching the sensor, it is 
easy to feel the sensor by palpation. Re-establishment 
of the sensor is carried out on the other arm. Patients 
were eager to use the CGM system. Eversense CGM 
system was mostly indicated for patients with a fear 
of hypoglycemia, glycemic instability and aversion to 
frequent glycemic measurements in self-control, poor 
tolerance of traditional transcutaneous sensors or for 
patients practicing competitive sports.
In all centers, no permanent complications were 
found during the implementation or removal of the 
sensors. In two patients a transient slight lipodystro-
phy was observed after sensor removal. In one case, 
the wound was sewn together at the request of a very 
sport active patient.
In the opinion of doctors from all centres, the use 
of Eversense contributed to the improvement of the 
effects of therapy, expressed as the time spent in the 
target blood glucose values. They emphasize the com-
fort and usefulness for the patients practicing sports. 
Patients experience in Poland
Roche Diabetes Care with the cooperation of 
Biostat, conducted a study to investigate the patients’ 
opinion about Eversense CGM system [27]. The study 
was aimed at gathering information about the Ever-
sense system and the impact of CGM on the life of a 
patient with diabetes. Advantages and disadvantages 
of the system and its individual components have also 
been evaluated. There were 86 enrolled patients who 
used the Eversense system for three months and then 
answered questions in the questionnaire. The study 
included almost as many men as women (48.8% vs. 
51.2%). Among the respondents, the largest group 
were patients aged 30–39 (27.9%). About 22.1% of 
the respondents were between 18 and 29 years old. 
The smallest group of patients were people aged 50–59 
(5.8%). About half of the patients (51.2%) had prior 
experience with CGM system. 
Patients were also asked to rate the system compo-
nents. In one of the questions, patients had to evalu-
ate the sensor’s activity time. Every third respondent 
(33.7%) rated the sensor activity very well, and 39.5% 
assessed it well. According to 16.3% of respondents, 
the sensor activity time was medium, and respectively 
7% and 2.3% of the respondents considered this ele-
ment of the system to be rather weak and weak. 
However, it should be emphasized that patients used 
a previous version of sensor which was implanted for 
3 months. Over three fourth of the respondents rated 
the alarms positively: 37.2% very well and 41.9% good. 
About 11% of patients considered it as medium, 4.6% 
as rather weak, and 3.5% as weak. 
One of the reasons for traditional CGMs limited 
use include a perceived burden of frequent insertions, 
fear of pain or discomfort during an implantation 
procedure. Therefore, patients were asked to evalu-
ate a method for inserting sensor. Over half of the 
respondents considered the insertion of the sensor 
as very good (54.6%), moreover, according to 30.2% 
people, this method was good. About 8.1% of patients 
assessed the insertion of the sensor on medium rate, 
5.8% as rather poorly and only 1.2% poorly.
Education is the core to fully understanding and 
integrating a CGM into daily practice and patients’ 
lifestyles. Training on CGM is important to ensure 
that patients know how to use the device and set the 
appropriate expectations. The educational training in 
the use of system operation received particularly posi-
tive marks. As many as 83.7% of people evaluated the 
training very well, and 15.1% of people — well. Only 
one person (1.2%) considered the training to be poor.
Patients were also asked to answer the question: 
“What benefits do you see in using the Eversense sys-
tem for therapy?”. More than 34% of respondents in-
dicated the possibility of continuous control and access 
to blood glucose level measurements. About 17.9% of 
patients indicated benefits related to warning alarms. 
Other significant benefits of the system in the respond-
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ents’ opinion were: displaying glucose trends (10.1%), 
limited number of SMBG measurements (7.7%), user-
friendly application or the possibility of glycemic control 
during physical activities or sleep (5.4%).
However, most importantly, 87.2% of respond-
ents confirmed that the use of the Eversense system 
had a positive impact on their daily life with diabetes. 
Respondents indicated that the use of the Eversense 
CGM system allows for easy glycemic monitoring, bet-
ter maintaining of target glucose level and improve-
ment of the quality of life (each of these answers were 
indicated by 15.4% of patients). The reduction in the 
number of finger pricks was indicated by 12.5%. About 
5% of patients appreciated the usefulness of Eversense 
system in the prevention of hypo- and hyperglycemia 
and assistance in the selection of meals. Almost 4% of 
people indicated safety, psychological comfort, more 
precise adjustment of insulin doses and the ability to 
monitor blood glucose even at night.
Despite good ratings of the Eversense CGM system, 
only 39.5% of patients declared that they intend to 
continue using the Eversense system. Patients were 
asked why they do not intend to use Eversense system. 
The vast majority of patients (65.1%) indicated a too 
high price and lack of reimbursement.
Global reimbursement of CGM 
Clinical studies demonstrated that the use of 
CGM could reduce hyperglycemia and hypoglycemia 
episodes by providing the patients information about 
blood glucose levels as well as the rate and direction of 
glycemia changes. Randomized controlled trials have 
shown that these electronic devices can be also helpful 
in lowering the HbA1c level without increasing the risk 
of hypoglycemia in patients with T1DM. Despite the 
fact that the evidence base for CGM clinical efficacy has 
grown, coverage by global reimbursement authorities is 
still limited. It is associated with a lack of independent, 
robust, randomized clinical trials demonstrating both 
improved outcomes for hyperglycemia and hypoglyce-
mia in specific patient populations. Moreover, there is 
only limited data on cost-effectiveness of CGM systems 
published. Reimbursement by payers is critical for the 
uptake and use of new diabetes technologies which can 
decrease the risk of acute and chronic complications 
of diabetes. Assuming that the daily costs for CGM us-
age are of approximately $5–10 per day, this account 
for $3,000 per year per patient. In some European 
countries the cost is around 4,000€ per year [28, 29].
However, recently CGM is reimbursed in the United 
States. In the US, national health insurance program 
(Medicare) covers CGM and related supplies instead 
of blood glucose meters for making diabetes treat-
ment decisions. Coverage criteria include intensively 
insulin treated patients who perform four or more 
SMBG/day, are taking multiple insulin injections or 
are using an insulin pump, and will require frequent 
adjustment of insulin dose based on the reading from 
CGM [29]. 
CGM sensors are also reimbursed in many Eu-
ropean countries. In England, National Institute for 
Health and Care Excellence (NICE) published clinical 
guidelines covering the management of type 1 diabetes 
in adults and children. It was recommended that CGM 
should be offered to people with challenging or severe 
hypoglycemia, to those with impaired awareness or fear 
of hypoglycemia, and to those for whom self-monitoring 
of blood glucose has failed to achieve optimum results. 
Recently, in Germany, real time CGM systems are re-
imbursed for T1DM and T2DM treated with insulin. In 
a few European countries (e.g., Slovenia, Spain), reim-
bursement of CGM is limited to pediatric population [29].
CGM reimbursement in Poland
Reimbursement of CGM in Poland is still limited. 
The National Health Fund covers the rtCGM for children 
and adults under 26 years old with T1DM, treated with 
insulin pump. Coverage criteria only include patients 
with hypoglycemia unawareness (lack of prodromal 
symptoms of hypoglycemia after alcohol consumption 
was excluded) [30]. 
Unfortunately, current regulations prevent patients 
from accessing the Eversense CGM system in this pa-
tient group. This provision stipulates that the limit for 
sensors is PLN 600 per month, up to 4 pieces per month 
and a patient surcharge of 30% of the limit value. In the 
current wording, both the description of the medical 
device, the limit of financing from public funds and the 
period of use have been formulated without the fact 
that other CGM systems with a period of use longer 
than a week are already available on the Polish market. 
This provision prevents the reimbursement concerning 
Eversense CGM from being carried out and settled by 
the National Health Fund.
FGM is reimbursed only for children from 4 to 18 
years old with type 1 diabetes mellitus with very well 
monitored blood glucose, i.e. at least 8 blood glucose 
measurements per day [31].
It should be emphasized that huge proportions of 
the adult T1DM population are identified with persis-
tent poor glycemic control (glucose level fluctuations, 
hypoglycemia episodes). Limited reimbursement influ-
ences the limited access of patients with diabetes to 
these devices and could worsen their prognosis. 
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Conclusions
Continuous glucose monitoring systems have 
revolutionized the treatment and monitoring of 
diabetes. These devices are especially recommended 
for diabetic patients treated with insulin. According 
to Diabetes Poland guidelines, use of CGM is indi-
cated in patients with recurrent episodes of severe 
hypoglycemia or large circadian variation of blood 
glucose levels. CGM systems provide patients detailed 
information about the level of glucose and thus can 
reduce the risk of hypoglycemia and improve patient 
quality of life. 
Eversense CGM is the only one system which is 
approved for long-term use (up to 180 days). The 
subcutaneous session implantation procedure proved 
to be simple and uncomplicated. This CGM system can 
be recommended in particular to patients who, due 
to their profession and sports discipline, cannot or do 
not want to use traditional transcutaneous sensors. 
Further groups are the patients with skin reactions as-
sociated with the use of traditional sensors or people 
who perceive frequent sensor replacement as a burden 
or benefited from on-body vibration alerts.
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